

**Table 1.** Socio-demographic and clinical characteristics of the study population (n=151,674 ) by geographical origin and sex at baseline and during follow-up.

<b>MEN 110,592(72.9%)</b>	NAT		WEWC		EE		NAME		SSA		LA		CRB		ASIA/OC	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
NUMBER	86,670		2,806		1,119		1,740		10,434		4,185		1,792		1,846	
% of men	(78.4)		(2.5)		(1.0)		(1.6)		(9.4)		(3.8)		(1.6)		(1.7)	
% of migrant men	-		(11.7)		(4.7)		(7.3)		(43.6)		(17.5)		(7.5)		(7.7)	
<b>BASELINE</b>																
Age [years, Me(IQR)]	37.0	(31.0-44.1)	37.8	(31.7-44.4)	31.8	(27.2-37.4)	37.6	(31.5-45.1)	36.7	(31.2-42.6)	33.2	(28.2-39.3)	37.2	(30.5-44.4)	34.3	(29.1-40.9)
Transmission																
MSM	53,657	(61.9)	1,637	(58.3)	536	(47.9)	542	(31.2)	1,012	(9.7)	3,172	(75.8)	703	(39.2)	1,111	(60.2)
PWID/OTH	10,453	(12.1)	330	(11.8)	251	(22.4)	281	(16.2)	733	(7.0)	112	(2.7)	33	(1.8)	139	(7.5)
HTX	16,509	(19.1)	481	(17.1)	221	(19.8)	741	(42.6)	7,951	(76.2)	715	(17.1)	927	(51.7)	426	(23.1)
UNK	6,051	(7.0)	358	(12.8)	111	(9.9)	176	(10.1)	738	(7.1)	186	(4.4)	129	(7.2)	170	(9.2)
CD4 count [cells/μl, Me(IQR)]	382	(205-564)	365	(171-570)	397	(248-552)	297.5	(119-493.5)	254	(110-416)	368	(200-551)	319	(132-490)	335	(165-510)
Viral Load [log 10 copies/ml, Me(IQR)]	4.7	(4.0-5.2)	4.7	(4.0-5.2)	4.5	(3.9-5.0)	4.8	(4.1-5.3)	4.7	(3.9-5.2)	4.6	(4.0-5.1)	4.6	(3.9-5.1)	4.6	(3.9-5.1)
AIDS	8,904	(10.3)	297	(10.6)	96	(8.6)	277	(15.9)	1,496	(14.3)	465	(11.1)	217	(12.1)	214	(11.6)
HBV DNA and/or Ab (excluding sAB)																
Yes	18,298	(21.1)	763	(27.2)	397	(35.5)	357	(20.5)	3,086	(29.6)	1,380	(33.0)	371	(20.7)	515	(27.9)
No	48,782	(56.3)	1,275	(45.4)	469	(41.9)	1,078	(62.0)	5,248	(50.3)	2,394	(57.2)	1,128	(63.0)	864	(46.8)
Unknown	19,590	(22.6)	768	(27.4)	253	(22.6)	305	(17.5)	2,100	(20.1)	411	(9.8)	293	(16.4)	467	(25.3)
HCV RNA and/or Ab																
Yes	13,582	(15.7)	445	(15.9)	300	(26.8)	299	(17.2)	476	(4.6)	294	(7.0)	71	(4.0)	185	(10.0)
No	53,793	(62.1)	1,520	(54.2)	546	(48.8)	1,115	(64.1)	7,465	(71.5)	3,400	(81.2)	1,422	(79.4)	1,186	(64.3)
Unknown	19,295	(22.3)	841	(30.0)	273	(24.4)	326	(18.7)	2,493	(23.9)	491	(11.7)	299	(16.7)	475	(25.7)
Period																
1997-1999	16,826	(19.4)	311	(11.1)	38	(3.4)	282	(16.2)	1,216	(11.7)	233	(5.6)	208	(11.6)	170	(9.2)
1999-2003	19,484	(22.5)	615	(21.9)	140	(12.5)	402	(23.1)	3,150	(30.2)	617	(14.7)	537	(30.0)	354	(19.2)
2004-2008	31,128	(35.9)	1,146	(40.8)	450	(40.2)	653	(37.5)	4,103	(39.3)	1,800	(43.0)	756	(42.2)	790	(48.2)
2009-2013	19,232	(22.2)	734	(26.2)	491	(43.9)	403	(23.2)	1,965	(18.8)	1,535	(36.7)	291	(16.2)	532	(28.8)
<b>FOLLOW-UP</b>																
StartedcART	68,130	(78.6)	2,063	(73.5)	726	(64.9)	1,410	(81.0)	8,128	(77.9)	2,954	(70.6)	1,265	(70.6)	1,354	(73.4)
# with only baseline CD4	29,904	(34.5)	987	(35.2)	363	(32.4)	708	(40.7)	4,263	(40.9)	1,401	(33.5)	553	(30.9)	576	(31.2)
# CD4 cell count measurements[Me(IQR)]	2	(1-6)	2	(1-6)	3	(1-6)	2	(1-5)	2	(1-4)	2	(1-5)	2	(1-6)	2	(1-6)

<b>WOMEN</b> <b>41,082 (27.1%)</b>	NAT		WEWC		EE		NAME		SSA		LA		CRB		ASIA/OC	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
NUMBER	19,592		633		624		616		16,197		1,113		1,379		928	
% of women	(47.7)		(1.5)		(1.5)		(1.5)		(39.4)		(2.7)		(3.4)		(2.3)	
% of migrant wom.	-		(2.9)		(2.9)		(2.9)		(75.4)		(5.2)		(6.4)		(4.3)	
<b>BASELINE</b>																
Age [years, Me(IQR)]	34.7	(28.7-42.2)	35.2	(29.3-43.0)	30.2	(25.6-36.0)	35.5	(28.4-44.7)	31.6	(27.0-37.5)	33.2	(27.6-40.1)	35.1	(28.5-43.3)	31.8	(27.5-37.9)
Transmission																
PWID/OTH	3,554	(18.1)	133	(21.0)	91	(14.6)	40	(6.5)	1,062	(6.6)	52	(4.7)	26	(1.9)	145	(15.6)
HTX	14,448	(73.7)	406	(64.1)	464	(74.4)	517	(83.9)	14,234	(87.9)	981	(88.1)	1,225	(88.8)	718	(77.4)
UNK	1,590	(8.1)	94	(14.9)	69	(11.1)	59	(9.6)	901	(5.6)	80	(7.2)	128	(9.3)	718	(7.0)
CD4 count [cells/μl, Me(IQR)]	380	(199-577)	360	(194-550)	362.5	(217.5-546.5)	328.5	(159-532.5)	293	(157-456)	330	(160-522)	341	(169-527)	266.5	(86-453)
Viral Load [log 10 copies/ml, Me(IQR)]	4.3	(3.6-5.0)	4.4	(3.5-5.0)	4.2	(3.6-4.9)	4.4	(3.6-5.1)	4.3	(3.5-4.9)	4.4	(3.7-4.9)	4.2	(3.5-4.8)	4.5	(3.7-5.0)
AIDS	1,949	(10.0)	63	(10.0)	62	(9.9)	70	(11.4)	1,501	(9.3)	130	(11.7)	126	(9.1)	148	(16.0)
HBV DNA and/or Ab (excluding sAB)																
Yes	2,342	(12.0)	112	(17.7)	144	(23.1)	97	(15.8)	3,771	(23.3)	164	(14.7)	99	(7.2)	241	(26.0)
No	12,573	(64.2)	326	(51.5)	327	(52.4)	440	(71.4)	9,004	(55.6)	809	(72.7)	1,067	(77.4)	401	(43.2)
Unknown	4,677	(23.9)	195	(30.8)	153	(24.5)	79	(12.8)	3,422	(21.1)	140	(12.6)	213	(15.5)	286	(30.8)
HCV RNA and/or Ab																
Yes	4,139	(21.1)	133	(21.0)	157	(25.2)	41	(6.7)	571	(3.5)	82	(7.4)	28	(2.0)	54	(5.8)
No	11,197	(57.2)	301	(47.6)	322	(51.6)	488	(79.2)	11,589	(71.6)	864	(77.6)	1,108	(80.4)	536	(57.8)
Unknown	4,256	(21.7)	199	(31.4)	145	(23.2)	87	(14.1)	4,037	(24.9)	167	(15.0)	243	(17.6)	338	(36.4)
Period																
1997-1999	5,097	(26.0)	90	(14.2)	20	(3.2)	96	(15.6)	1,717	(10.6)	105	(9.4)	177	(12.8)	115	(12.4)
1999-2003	5,679	(29.0)	191	(30.2)	92	(14.7)	157	(25.5)	5,292	(32.7)	230	(20.7)	458	(33.2)	265	(28.6)
2004-2008	5,998	(30.6)	215	(34.0)	244	(39.1)	239	(38.8)	6,565	(40.5)	509	(45.7)	607	(44.0)	373	(40.2)
2009-2013	2,818	(14.4)	137	(21.6)	268	(43.0)	124	(20.1)	2,623	(16.2)	269	(24.2)	137	(9.9)	175	(18.9)
<b>FOLLOW-UP</b>																
StartedcART	16,020	(81.8)	491	(77.6)	463	(74.2)	521	(84.6)	13,227	(81.7)	878	(78.9)	1,136	(82.4)	811	(87.4)
# with only baseline CD4	7,602	(38.8)	265	(41.9)	252	(40.4)	276	(44.8)	6,237	(38.5)	466	(41.9)	508	(36.8)	383	(41.3)
# CD4 cell count measurements[Me(IQR)]	2	(1-5)	2	(1-5)	2	(1-4)	2	(1-5)	2	(1-4)	2	(1-4)	2	(1-4)	2	(1-4)

Me(IQR): Median (Interquartile Range); NAT: person originally from the country of enrolment; WEWC: Western Europe and other Western countries, including North America, Australia and New Zealand; EE: Eastern Europe; NAME: North Africa and The Middle East; SSA: Sub-Saharan Africa; LA: Latin America; CRB: The Caribbean; ASIA:

the Asian Continent; UNK: unknown; MSM: Men who have sex with men; PWID: People who inject Drug Users; HTX: Heterosexual transmission; HBV: Hepatitis B virus; HCV: Hepatitis C virus; Ab: antibody; sAb: surface antibody; Start cART: does patient start combined antiretroviral therapy during follow-up.

**Table 2.** Probability of initiating cART for migrant men and women of different geographical origins living in Western Europe compared to native men and women, respectively: Results from multivariable Cox models. Adjusted Hazard Ratios and 95% Confidence Intervals for cART initiation are shown overall, and by CD4 cellcount at recruitment where the test for interaction between geographical origin and CD4 count at recruitment was statistically significant.

	WEWC	EE	NAME	SSA	LA	CRB	ASIA/OC
	aHR (95%CI) p-value	aHR (95%CI) p-value	aHR (95%CI) p-value	aHR (95%CI) p-value	aHR (95%CI) p-value	aHR (95%CI) p-value	aHR (95%CI) p-value
<b>MEN</b>							
Effect of GO vs. NAT*	0.94 [0.90-0.99] p=0.01‡	0.87 [0.80-0.93] P<0.01‡	0.92 [0.88-0.97] p<0.01‡	0.90 [0.87-0.92] p<0.01‡	0.98 [0.95-1.02] p=0.39‡	0.77 [0.73-0.82] p<0.01‡	0.94 [0.89-1.00]* p=0.04‡
Interaction test	p=0.9603†	p=0.0362†	p=0.1845†	p=0.0000†	p=0.5615†	P=0.0000†	P=0.4654†
>500		0.70 [0.60-0.83] P<0.01‡		0.75 [0.70-0.81] p<0.01‡		0.55 [0.47-0.64] p<0.01‡	
350-500		0.89 [0.76-1.03] p=0.11‡		0.80 [0.76-0.85] p<0.01‡		0.60 [0.53-0.69] p<0.01‡	
250-350		0.96 [0.82-1.13] p=0.65‡		0.96 [0.91-1.02] p=0.20‡		0.85 [0.73-0.98] p=0.02‡	
100-250		0.96 [0.82-1.14] p=0.67‡		0.98 [0.93-1.02] p=0.27‡		0.97 [0.87-1.08] p=0.58‡	
<100		0.88 [0.72-1.07] p=0.20‡		0.90 [0.86-0.94] p<0.01‡		0.90 [0.81-0.99] p=0.04‡	
<b>WOMEN</b>							
Effect of GO vs. NAT*	1.01 [0.93-1.11] p=0.79‡	1.01 [0.91-1.11] p=0.91‡	0.94 [0.86-1.02] p=0.14‡	1.03 [1.00-1.06] p=0.03‡	0.93 [0.87-1.00] p=0.05‡	0.99 [0.93-1.05] p=0.63‡	0.98 [0.91-1.05] p=0.60‡
Interaction test	p=0.0471†	p=0.9905†	p= 0.0269†	p=0.0000†	P=0.4689†	P= 0.0473†	P=0.3215†
>500	1.02 [0.84-1.23] p=0.87‡		0.90 [0.74-1.09] p=0.28‡	1.31 [1.24-1.38] p<0.01‡		1.14 [1.00-1.29] p=0.05‡	
350-500	1.32 [1.09-1.60] p<0.01‡		0.74 [0.60-0.90] p<0.01‡	1.05 [1.00-1.11] p=0.06‡		1.06 [0.93-1.22] p=0.37‡	
250-350	0.90 [0.73-1.13] p=0.38‡		0.91 [0.74-1.14] p=0.42‡	1.00 [0.94-1.06] p=0.99‡		0.94 [0.81-1.08] p=0.36‡	
100-250	1.00 [0.83-1.22] p=0.97‡		1.08 [0.90-1.29] p=0.42‡	0.94 [0.90-0.99] p=0.01‡		0.92 [0.81-1.05] p=0.21‡	
<100	0.87 [0.71-1.08] p=0.20‡		1.11 [0.91-1.34] p=0.31‡	0.91 [0.86-0.96] p<0.01‡		0.88 [0.77-1.02] p=0.10‡	

WEWC: Western Europe and other Western countries in North America, Australia and New Zealand; EE: Eastern Europe; NAME: North Africa and The Middle East; SSA: Sub-Saharan Africa; LA: Latin America; CRB: The Caribbean; ASIA/OC: the rest of the Asian Continent and Oceania. All models are adjusted for baseline variables: calendar period, age, transmission category, viral load, AIDS stage, and history of hepatitis B and hepatitis C infection. \*Models also adjusted by CD4 count at recruitment. †p-value for the likelihood ratio test for interaction between geographical origin and CD4 count; ‡p-value for the Wald's test for the Hazard Ratio of each geographical origin compared to native population